Jaguar Health (JAGX) Competitors

Hookipa Pharma (NASDAQ:HOOK) and Jaguar Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Do insiders & institutionals have more ownership in HOOK or JAGX?

63.9% of Hookipa Pharma shares are held by institutional investors. Comparatively, 12.0% of Jaguar Health shares are held by institutional investors. 5.8% of Hookipa Pharma shares are held by company insiders. Comparatively, 0.2% of Jaguar Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Do analysts prefer HOOK or JAGX?

Hookipa Pharma presently has a consensus target price of $4.67, suggesting a potential upside of 472.32%. Given Jaguar Health's higher possible upside, analysts plainly believe Hookipa Pharma is more favorable than Jaguar Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hookipa Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jaguar Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the MarketBeat Community prefer HOOK or JAGX?

Jaguar Health received 1750 more outperform votes than Hookipa Pharma when rated by MarketBeat users. Likewise, 89.08% of users gave Jaguar Health an outperform vote while only 69.11% of users gave Hookipa Pharma an outperform vote.

Company	Underperform	Outperform
Hookipa Pharma	Outperform Votes 85 69.11%	Underperform Votes 38 30.89%
Jaguar Health	Outperform Votes 1835 89.08%	Underperform Votes 225 10.92%

Which has more risk and volatility, HOOK or JAGX?

Hookipa Pharma has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Jaguar Health has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Which has stronger valuation & earnings, HOOK or JAGX?

Jaguar Health has lower revenue, but higher earnings than Hookipa Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hookipa Pharma	$20.13M	4.01	-$81.58M	-$0.50	-1.63
Jaguar Health	$9.76M	7.32	-$41.30M	N/A	N/A

Does the media favor HOOK or JAGX?

In the previous week, Jaguar Health had 5 more articles in the media than Hookipa Pharma. MarketBeat recorded 8 mentions for Jaguar Health and 3 mentions for Hookipa Pharma. Jaguar Health's average media sentiment score of 0.59 beat Hookipa Pharma's score of 0.14 indicating that Hookipa Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hookipa Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jaguar Health	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is HOOK or JAGX more profitable?

Hookipa Pharma has a net margin of -88.73% compared to Hookipa Pharma's net margin of -377.95%. Jaguar Health's return on equity of -33.33% beat Hookipa Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hookipa Pharma	-88.73%	-33.33%	-20.22%
Jaguar Health	-377.95%	-642.15%	-75.53%

Summary

Hookipa Pharma beats Jaguar Health on 10 of the 15 factors compared between the two stocks.